Hypofractionated Chemoradiotherapy for Cervical Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to evaluate whether hypofractionated whole pelvic or extended-field concurrent chemoradiotherapy can improve treatment access and efficiency while potentially providing superior oncologic efficacy and safety compared to conventional chemoradiotherapy in patients with early-stage node-positive and locally advanced cervical cancer. Building on encouraging safety and efficacy outcomes from our Phase II HYPOCx-iRex trial (TCTR20210812003), this study will provide data for a critical evidence gap regarding the safety, feasibility, and oncologic efficacy of hypofractionated radiotherapy, including extended-field para-aortic treatment, delivered with concurrent chemotherapy. The main questions it aims to answer are: * Does hypofractionated chemoradiotherapy achieve superior nodal control compared to conventional chemoradiotherapy? * Does hypofractionated chemoradiotherapy achieve superior overall survival compared to conventional chemoradiotherapy? Researchers will compare patients receiving hypofractionated external beam radiotherapy to those receiving conventional fractionation to evaluate if the shortened hypofractionated schedule provides comparable disease control, acceptable toxicity, improved quality of life, and cost-effectiveness. Participants will: * Be randomized to receive either hypofractionated external beam radiotherapy or conventional fractionation radiotherapy, both delivered using modern IMRT/VMAT techniques targeting either the whole pelvis or extended fields (including para-aortic lymph nodes). * Receive concurrent platinum-based chemotherapy during external beam radiation. * Complete image-guided adaptive brachytherapy following external beam radiotherapy. * Attend scheduled follow-up visits to evaluate tumor response, disease control, treatment-related toxicities, quality of life, and survival outcomes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak szyjki macicy kwalifikujący się do leczenia napromienianiem połączonym z chemią
- •Potwierdzony biopsją rak płaskonabłonkowy, gruczołowy lub mieszany szyjki macicy
- •Zaawansowana postać raka (stadium IA1-IVA wg wytycznych międzynarodowych)
- •Wykonane badania MRI miednicy w momencie rozpoznania
- •Badania obrazowe brzucha (MRI, CT lub PET-CT) w momencie rozpoznania
- •Prawidłowa funkcja nerek (GFR ≥ 50 mL/min)
- •Świadoma zgoda pacjenta na uczestnictwo
✗ Disqualifies
- •Inne nowotwory złośliwe (z wyjątkiem zmian przedrakowych szyjki macicy i raka skóry)
- •Przerzuty raka do części brzucha poza głównym obszarem leczenia
- •Wcześniejsze napromienianie miednicy lub brzucha
- •Wcześniejsze usunięcie macicy
- •Równoczesne napromienianie i operacja chirurgiczna
- •Kontraindykacje do badań MRI
- •Pacjenci nie mogą otrzymywać chemioterapii przed głównym leczeniem (poza planowaną chemią podczas napromieniania)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 24, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Siriraj Hospital
Bangkok Noi, Thailand
Trial contact
Tissana Prasartseree, MD
Pittaya Dankulchai, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.